NovelStem Increases NewStem Ownership to 27.3% Following Achievement of Development Milestones for Stem-Cell-Based Cancer Treatments Resistance Diagnostic

Press Release – December 16, 2019

BOCA RATON, Fla. and JERUSALEM, Israel, Dec. 16, 2019 (GLOBE NEWSWIRE) — NovelStem International Corp. (OTC Pink: NSTM), a biotechnology company focused on stem-cell-based diagnostic technology to aid the selection of cancer therapeutic agents being developed by its Israel-based affiliate, NewStem Ltd., today announced it has completed a $1 million follow-on investment in NewStem, increasing its ownership in NewStem to 27.3% from 20%.